acquired resistance to anti-egfr therapy in colorectal cancer
Published 2 years ago • 166 plays • Length 1:33Download video MP4
Download video MP3
Similar videos
-
1:30
overcoming acquired resistance to targeted therapy in colorectal cancer
-
16:56
colorectal cancer with acquired resistance to egfr antibodies: how to manage?
-
6:36
detecting resistance to egfr rechallenge in ras/raf wt crc
-
2:14
anti-egfr rechallenge therapy with or without trametinib in addition to panitumumab in advanced crc
-
2:07
acquired resistance to egfr antibodies
-
2:10
anti-egfr therapy for ras wild-type left-sided colorectal cancer
-
1:48
acquired resistance to third-generation egfr tkis in nsclc
-
0:51
addressing resistance to icis in colorectal cancer
-
3:50
mechanisms of resistance to efgr antibodies in mcrc
-
5:05
is front-line anti-egfr therapy essential in ras-wt mcrc?
-
1:43
complex roles of noncoding rnas in colorectal cancer resistance to anti-egfr therapy
-
5:16
mitigating resistance in kras-driven cancers
-
1:02
exciting updates from asco 2022 in the anti-egfr rechallenge space for colorectal cancer
-
1:47
updates on biomarkers of resistance to crc treatment
-
0:37
response to systemic anti-cancer therapy in uncommon egfr mutations
-
0:54
targeted therapies in colorectal cancer
-
2:30
acquired resistance to osimertinib in egfr nsclc - 2022 program: targeted therapies forum - english
-
3:08
targeting less common mutations in colorectal cancer
-
24:36
treatment options for egfr t790m negative acquired resistance